Abstract
We assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs. beta-lactam plus doxycycline for the treatment of community-acquired pneumonia (CAP) among patients in the Australian Community-Acquired Pneumonia Study. Both regimens demonstrated similar outcomes against CAP due to either 'atypical' (Chlamydophila, Legionella or Mycoplasma spp.) or typical bacterial pathogens.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use
-
Australia / epidemiology
-
Chlamydophila / pathogenicity
-
Community-Acquired Infections / drug therapy*
-
Community-Acquired Infections / epidemiology
-
Community-Acquired Infections / microbiology
-
Doxycycline / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Gram-Negative Bacterial Infections / drug therapy
-
Gram-Negative Bacterial Infections / epidemiology
-
Gram-Negative Bacterial Infections / microbiology
-
Humans
-
Legionella / pathogenicity
-
Macrolides / therapeutic use*
-
Male
-
Middle Aged
-
Mycoplasma / pathogenicity
-
Mycoplasma Infections / drug therapy
-
Mycoplasma Infections / epidemiology
-
Mycoplasma Infections / microbiology
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / epidemiology
-
Pneumonia, Bacterial / microbiology
-
Prospective Studies
-
Severity of Illness Index
-
Treatment Outcome
-
Young Adult
-
beta-Lactams / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Macrolides
-
beta-Lactams
-
Doxycycline